Repros Therapeutics — Investor Presentation (November 2016)
37 slides from Repros Therapeutics's investor presentation, Nov 15, 2016
Slide 1: Repros Therapeutics
Repros Therapeutics Development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by Repros Therapeutics Inc . (“Repros” or the “Company”) that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
Slide 3: Proellex: Addressing significant unmet female reproductive disorders
Proellex® Addressing significant unmet female reproductive disorders
Slide 4: Uterine Fibroids & Endometriosis
Uterine Fibroids & Endometriosis Poor therapeutic options for debilitating female disorders experienced by women in the prime of their life • Benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus • Most common tumor of the female reproductive tract – Heavy bleeding / anemia – Abd
Slide 5: How Antiprogestins Like Proellex Work
O O OMe N OAc CH 3 H 3 C How Antiprogestins Like Proellex Work Antiprogestins • Selectively block progesterone activity • Allow tonic hormone secretions – Alleviate negative side effects of GnRHa • Potential for chronic use Different than GnRH agonists and antagonists. These agents: • Block hypothal
Slide 6: An Effective Dose of Proellex Stops Menstruation in Majority of Women
An Effective Dose of Proellex Stops Menstruation in Majority of Women Induction of amenorrhea relieves key symptoms of uterine fibroids and endometriosis 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea (no ovulatio
Slide 7: Impact of Proellex Treatment on Uterine Fibroids
Impact of Proellex Treatment on Uterine Fibroids -80 -60 -40 -20 0 20 40 60 80 100 120 % Amenorrhea % Reduction in Fibroid Volume % Effects of 12 mg Proellex after 36 weeks of treatment of severe uterine fibroids (menstrual blood loss > 80mL/ cycle) LOCF Analysis 12 mg Proellex Placebo p=0.0001 p=0.
Slide 8: Change in UFSQOL Over Time
Change in UFSQOL Over Time LOCF 0 10 20 30 40 50 60 70 80 90 Baseline End of Cycle 1 End of Cycle 2 Comparison of Quality of Life Outcomes Between Different Doses of Telapristone and Different Routes of Administration in Treatment of Uterine Fibroids Oral Pbo Oral 6mg Oral 12mg Vaginal Pbo Vaginal 6
Slide 9: Impact of Proellex Treatment on Endometriosis
Impact of Proellex Treatment on Endometriosis 0 2 4 6 8 10 12 14 Baseline End of 18 Wk Off Drug Interval Median Sum of BBSS Scored Menstrual Pain Over 28 Day Cycle Proellex Placebo p=0.0013 N=43 Proellex , 17 Placebo 47 in US, 13 in Argentina BBSS Classification Moderate to Severe
Slide 10: Impact of Proellex Treatment on Endometriosis
Impact of Proellex Treatment on Endometriosis -70 -60 -50 -40 -30 -20 -10 0 4 Wk 8 Wk 12 Wk 18 Wk LOCF Off Drug Interval Median % Change in Non - Prescription Analgesics Proellex Placebo p=0.0093 -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 4 Wk 8 Wk 12 Wk 18 Wk LOCF Off Drug Interval Median % Change
Slide 11: Key Advantage of Proellex Over Other Antiprogestins in Development
All other antiprogestins in development require off - drug - interval after 12 weeks of treatment Key Advantage of Proellex Over Other Antiprogestins in Development Proliferative Disordered Proliferative Benign Endometrial Hyperplasia Mutter et al, 2007 12.5mg Proellex No hyperplasia Estrogen over T
Slide 12: Proellex Evolution of Lead Compound
PROELLEX EVOLUTION OF LEAD COMPOUND O CH 3 O OMe N OAc CH 3 H 3 C 44 Analogues Synthesized to Date O CH 3 OH 3 C N OAc CH 3 H 3 C CDB - 2914 ( Ulipristal Acetate) • NIH precursor to Repros class • Allergan marketing molecule ( Esmya ) in Europe for treatment of uterine fibroids CDB - 4124 Proellex (
Slide 13: Differences Between Proellex and Esmya
Differences Between Proellex and Esmya • Proellex – Duration of drug cycle • 18 weeks – Formulation • Immediate release capsule: 12 mg – Tmax : 0.75 hr – Cmax : 256 ± 113 ng/ml – AUC: 935 ± 492 ng* hr /ml – NIH rabbit model • 95% suppression of progesterone action @ 8 mg oral – Induction of amenorrh
Slide 14: Differences Between Proellex and Esmya
Differences Between Proellex and Esmya Comparison of Proelle x and Esmya Treatment Age BMI Ethnicity % Amenorrhea % Fibroid Reduction UFSQOL Baseline UFSQOL End of Study Proellex (All US @ 36 wks , LOCF) 6 mg 40.55 33.67 100% Black 88.9 32.9% 77.1 33.5 12 mg 41.35 33.49 88.2% Black 94.1 58.2% 69.9 1
Slide 15: Proellex Clinical Goals
Proellex Clinical Goals • Confirm Phase 3 requirements with FDA • Uterine Fibroids: Request Mtg. Q4 - ’16 • Endometriosis : Request Mtg. Q4 - ’16 • Anticipate meetings Q1 - Q2 ‘17 • Completed Proellex NDA components • Pre - clinical complete (including 2 carcinogenicity studies) • Manufacturing comp
Slide 16: Proellex Summary
Proellex Summary • Potential Proellex market opportunity > $1 Billion for Fibroids and Endometriosis • Rigorous clinical program working to move into Phase 3 • Significant clinical advantages identified against GnRH agonists/antagonists • Longer symptom relief established against other approved or i
Slide 17: Encyzix (enclomiphene): Rational treatment for secondary hypogonadism
Encyzix ( enclomiphene ) Rational treatment for secondary hypogonadism
Slide 18: Enclomiphene Development Status
Enclomiphene Development Status • Central EU filing ongoing for treatment of secondary hypogonadism – Anticipated marketing authorization Q4 - ’17 • Repros to present as sponsor at 12/6/16 FDA Adcom – “Agenda : The committee will discuss appropriate clinical trial design features, including acceptab
Slide 19: Prescription Claims for Testosterone Products
CM - 19 Prescription Claims for Testosterone Products Nguyen et al N Eng J Med 2015 73% 9% 3%
Slide 20: Prevalence of Overweight and Obesity
CM - 20 Prevalence of Overweight and Obesity Global Burden of Disease Study 2013 (Ng et al Lancet 2014) Prevalence (%) 70 60 50 40 3 0 20 10 0 2 - 9 10 - 19 20 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79 ≥80 Age (years) 29.0 39.4 32.0 0 20 40 60 20-39 Years 40-59 Years ≥60 Years Percent CDC (Ogden,
Slide 21: Categorizing Gonadal Status by Testosterone and LH
CM - 21 0 20 40 60 80 LH (U/L) 0 10 20 30 40 50 Total Testosterone (nmol/L) Primary Hypogonadism Low T, high LH n=52 (1.7%) n = 3219 40 – 80 yr Categorizing Gonadal Status by Testosterone and LH Eugonadal Normal T and LH Compensated ‘Hypogonadism ’ Normal T, high LH Secondary Hypogonadism Low T, nor
Slide 22: BMI and Age: Different Effects on Hormones
CM - 22 EMAS Wu, JCEM 2008 BMI and Age: Different Effects on Hormones Testosterone ( nmol /L) LH (U/L) • With obesity, LH does not respond to fall in testosterone – functional hypothalamic / pituitary suppression • With aging , increasing LH compensates for failing testicular function so that any ag
Slide 23: Secondary Hypogonadism at Baseline
Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Secondary Hypogonadism at Baseline Age (years) BMI ≥ 25 - <30 kg/m2 BMI ≥ 30 kg/m2 Smoking (current) Alcohol (frequent) Morbidity ( ≥ 1) 0 5 10 15 *** *** * Poor morning erection Sexual thou
Slide 24: Obesity Related Hypogonadism is the Leading Cause of Secondary Hypogonadism
Obesity Related Hypogonadism is the Leading Cause of Secondary Hypogonadism • Obesity has been shown to attenuate LH pulse amplitude but maintain pulse frequency ( Vermeulen , JCEM,1993) • EMAS ( Tajar , JCEM, 2010) notes a decrease in the T:E ratio in secondary hypogonadal men compared to eugonadal
Slide 25: Weight Related Secondary Hypogonadism is Reversible with Weight Loss
Weight Related Secondary Hypogonadism is Reversible with Weight Loss CM - 18 n = 2395, *p<0.05, **p<0.01 % Weight loss Weight gain % 0 * ** * * * Camacho et al. European Journal of Endocrinolology 2013 Mean (SEM) Secondary Hypogonadism is REVERSIBLE with WEIGHT LOSS Secondary Hypogonadism DEVELOPS w
Slide 26: Relevant Experience Gleaned during Development of Enclomiphene
Relevant Experience Gleaned during the Development of Enclomiphene for the Treatment of Secondary Hypogonadism in Overweight or Obese Men All studies enrolled secondary hypogonadal men – Morning T <300 ng/ dL – LH < 9.4 mIU /mL – BMI > 25 – Age < 60 years Screening failures: Lessons learned from
Slide 27: Enclomiphene and Topical Testosterone Exhibit Different Effects on LH
0 100 200 300 400 500 600 700 800 900 1000 0 5 10 15 20 Total Testosterone ( ng /dl) Hours T @ Baseline T @ 6 Weeks 0 100 200 300 400 500 600 700 800 900 1000 0 5 10 15 20 Total Testosterone (ng/ dL ) Hours T @ Baseline T @ 6 Weeks The Anti - estrogen Enclomiphene and Topical Testosterone Exhibit Di
Slide 28: Change from Baseline in FSH Phase 2/3 Pool
Change from Baseline in FSH Phase 2/3 Pool 3.1 - 2.5 0 -3 -2 -1 0 1 2 3 4 Enclomiphene AndroGel Placebo Median Change from Baseline (U/L) QEF - 38 n = 1180 114 327 p - value vs AndroGel < 0.0001 p - value vs Placebo < 0.0001
Slide 29: Change from Baseline in LH Phase 2/3 Pool
Change from Baseline in LH Phase 2/3 Pool 3.0 - 1.8 0.2 -3 -2 -1 0 1 2 3 4 Enclomiphene AndroGel Placebo Median Change from Baseline ( mIU /mL) p - value vs AndroGel < 0.0001 p - value vs Placebo < 0.0001 QEF - 38 n = 1179 109 328
Slide 30: The Effects of Topical T Treatment
The Effects of Topical T Treatment Enclomiphene restores normal testosterone levels and maintains sperm concentrations Kim 2015, BJU International
Slide 31: Percent Change in Testicular Volume by Orchidometry
5.1 6.8 - 6.8 - 2.2 10.7 5.4 -8 -6 -4 -2 0 2 4 6 8 10 12 ZA-304 ZA-305 Mean Percent Change from Baseline Enclomiphene AndroGel Placebo Percent Change in Testicular Volume by Orchidometry vs. AndroGel p = 0.0074 vs. AndroGel p = 0.0224 n = 41 43 45 44 42 41
Slide 32: Proof of Concept Diet & Exercise Study in Obese Hypogonadal Men
Phase 2 Proof of Concept “Diet & Exercise” Study in Obese Hypogonadal Men - Baseline Findings Screen 98 to enroll 50 15 Month Study • Enrollment (n=50 in 5 weeks @ 5 sites) • Demographics ( stdev ) – Age: 43.3 (9.2) – BMI: 36.8 (3.2) – Waist: 46.9” (4.1) – % Body Fat: 38.1 (5.2) • Hormonal Status –
Slide 33: How Enclomiphene Works
How Enclomiphene Works Enclomiphene blocks estrogen at the level of the H - P axis increasing LH levels which in turn increases endogenous production of T 0 1 2 3 4 5 6 7 Enclomiphene LH Androgel LH Median LH ( mIU /mL) Impact on LH in 16 Wk Study ZA - 304 Baseline End of Study 0 50 100 150 200 250
Slide 34: Interim Month Data
Interim 9 Month Data ZA - 205 30 31 32 33 34 35 36 37 38 39 Bl 3 mo 6 mo 9 mo 12 mo 15mo BMI BMI Over Time 12.5 mg 25 mg pbo 0 50 100 150 200 250 300 350 400 0 100 200 300 400 500 600 700 Scr BL 3 mo 6 mo 9 mo 12 mo 15 mo Composite PRO CLEIA Morning T (ng/ dL ) Morning T Over Time 12.5 mg 25 mg pbo
Slide 35: Interim Month Data: Lean Mass, LCMS T & Free T
Interim 6 Month Data Lean Mass, LCMS T & Free T 63.5 64 64.5 65 65.5 66 66.5 67 67.5 68 68.5 Baseline 6 Month 12 Month 15 Month Lean Mass by DXA (kg) 12.5 mg 25 mg Placebo 0 20 40 60 80 100 120 140 160 180 0 100 200 300 400 500 600 700 800 900 1000 Baseline 6 Month 12 Month 15 Month Free T ( pg /mL)
Slide 36: Repros Late Stage Assets
Repros Late Stage Assets Repros seeking regional or global development/commercialization partners
Slide 37: Financial Summary
Financial Summary • Cash and equivalents: (unaudited Sept. 30, 2016) $10.5 M • Cash used in 2016 through Sept. 30, 2016: $12.5 M • Cash runway: Q2 2017 • Current shares outstanding: 25.4 M shares
Repros Therapeutics — Investor Presentation (November 2016) on 6ix